Here are the 10-Q quarterly reports from Repare Therapeutics Inc. (RPTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RPTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPTX filings page.
Repare Therapeutics (RPTX) reported Q3 2025 results with net income of $3.3 million, led by $11.6 million of revenue from its Debiopharm license. Operating income was $1.1 million, supported by a $3.3 million gain from terminating a prior Debiopharm collaboration and $2.2 million of interest income. Basic and diluted EPS were $0.08.
Cash and cash equivalents were $72.8 million, with $39.8 million in marketable securities; total assets were $126.7 million and shareholders’ equity was $115.1 million. Year-to-date, the company recorded a net loss of $43.5 million and used $42.8 million in operating cash.
The company continued restructuring initiatives, incurring $1.8 million in Q3 and $8.5 million year-to-date. It also out‑licensed discovery platforms to DCx (9.99% equity stake and related rights) earlier in 2025.
Subsequent event: Repare signed a definitive agreement for acquisition by XenoTherapeutics. Holders will receive a cash payment per share based on cash at closing, plus one non‑transferable CVR per share; closing is subject to approvals and is expected in Q1 2026.
Repare Therapeutics (RPTX) – Q2 FY25 10-Q highlights
- Revenue collapsed to $0.25 m (Q2 24: $1.07 m; 1H 24: $53.5 m, benefited from a $40 m Roche milestone now absent).
- Expense discipline: R&D cut 53 % and G&A down 28 %, driving total operating costs to $23.7 m (-38 % YoY). Restructuring charges of $3.4 m reflect a workforce reduction of ~75 % by Q4 25.
- Earnings: Net loss narrowed to $16.7 m (-$0.39/sh) from $34.8 m; 1H loss $46.8 m.
- Liquidity: Cash & marketable securities of $109.5 m; management guides funding runway to 2027.
- Strategic monetisation: Out-licensed discovery platforms to DCx ( $1 m cash, $3 m receivable, 9.99 % equity, $5.7 m gain booked ). Post-quarter, licensed lunresertib to Debiopharm for $10 m upfront plus up to $257 m milestones and single-digit royalties.
- Pipeline focus: resources concentrated on Phase 1 programs RP-3467 (POLAR) and RP-1664 (LIONS); topline safety/efficacy data expected Q4 25.
- Other: Bristol-Myers Squibb paid a $0.25 m option fee for an additional druggable target.
Cost reductions and asset deals offset revenue loss, but future value hinges on early-stage clinical read-outs.